Emerson (St. Louis, Mo.; www.emerson.com) has acquired Bioproduction Group (Bio-G), a leader in simulation, modeling, and scheduling software for biomanufacturing. Bio-G’s scheduling and modeling systems combined with Emerson’s extensive life sciences technology and expertise portfolio will help companies bring therapies for cancer, diabetes and other illnesses to patients sooner.
Life sciences companies continually look to accelerate the production of patient therapies and the Bio-G Scheduling software helps them accurately predict future plant resource availability to optimize manufacturing production. The scheduling software delivers an instantaneous view, accessible across an organization, into the current and future state of the plant, providing decision support to help increase facility uptime and reduce schedule-related product losses.
By connecting analytics and modeling tools with data from automation and operations systems—including Emerson’s DeltaV™ distributed control system and Syncade manufacturing execution system—the scheduling software provides a unified view of operations, maintenance, quality, and corporate systems. Bio-G’s software will become a part of Emerson’s Plantweb™ digital ecosystem, a comprehensive IIoT portfolio that expands digital intelligence to the entire manufacturing enterprise.
“We continue to work closely with industry leaders to develop the manufacturing technologies and approaches needed for next-generation biomanufacturing. With this acquisition, we can deliver even more ways to accelerate life sciences manufacturing,” said Tom Snead, president of life sciences at Emerson.